-
1Academic Journal
المؤلفون: P. Vlasov N., V. Karlov A., I. Zhidkova A., D. Dmitrenko V., I. Rudakova G., T. Danilova V., V. Kalinin A., O. Grebenyuk V., A. Gertsen P., Ya. Zhuravlev S., A. Karas Yu., E. Paramonova N., I. Ponomareva V., O. Miguskina I., N. Sobyanina A., D. Sukhova V., Yu. Salomatin V., M. Ertakhova L., T. Goguadze M., A. Shamray P., П. Власов Н., В. Карлов А., И. Жидкова А., Д. Дмитренко В., И. Рудакова Г., Т. Данилова В., В. Калинин А., О. Гребенюк В., А. Герцен П., Я. Журавлев С., А. Карась Ю., Е. Парамонова Н., И. Пономарева В., О. Мигуськина И., Н. Собянина А., Д. Сухова В., Ю. Саломатин В., М. Ертахова Л., Т. Гогуадзе М., А. Шамрай П.
المساهمون: This article has been supported by Eisai. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication., Статья спонсируется ООО «Эйсай». Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также принятии решения о представлении статьи для публикации.
المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 3 (2020); 47-55 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 3 (2020); 47-55 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-3
مصطلحات موضوعية: perampanel, pharmacoresistant focal epilepsy, efficacy, tolerance, safety, adverse events, side effects, therapy retention, перампанел, фармакорезистентная фокальная эпилепсия, эффективность, переносимость, безопасность, нежелательные явления, побочные эффекты, удержание на терапии
وصف الملف: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1365/1056; https://nnp.ima-press.net/nnp/article/view/1365/1071; Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011 Mar;11(2):56-63. doi:10.5698/15357511-11.2.56.; Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi:10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2.; Krauss GL, Perucca E, Kwan P, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an openlabel extension of phase III randomized trials: Study 307. Epilepsia. 2018 Apr;59(4):866-76. doi:10.1111/epi.14044. Epub 2018 Mar 25.; French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology. 2015 Sep 15;85(11):950-7. doi:10.1212/WNL.0000000000001930.; Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. Epilepsia. 2018 Sep;59(9):1740-52. doi:10.1111/epi.14522. Epub 2018 Jul 31.; Инструкция по медицинскому применению лекарственного препарата перампанел от 29.03.2019. ЛП-002200.; Patsalos PN. Drug Interactions With the Newer Antiepileptic Drugs (AEDs) - Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs. Clin Pharmacokinet. 2013 Nov;52(11):927-66. doi:10.1007/s40262-013-0087-0.; Карлов ВА. Клиническая фармакология АЭП. В кн.: Эпилепсия у детей и взрослых женщин и мужчин. Руководство для врачей. Москва: Бином; 2019. С. 753-66.; Карлов ВА, Беляев ОВ, Власов ПН и др. Российский опыт применения перампанела в повседневной клинической практике. Неврология нейропсихиатрия психосоматика. 2016;8(1S):11-7. doi:10.14412/2074-2711-2016-1S-11-17; Swiderska N, Tana HJ, Rajaib A, et al. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study. Seizure. 2017 Nov;52:63-70. doi:10.1016/j.seizure.2017.08.014. Epub 2017 Sep 14.; Sierdzan K, Hodgson H. Efficacy and tolerability of perampanel in patients with refractory partial epilepsy in a tertiary epilepsy centre. Epilepsia 2014;55:137.; Villanueva V, Garces M, Lopez-Gonzalez FJ, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res. 2016 Oct;126:201-10. doi:10.1016/j.eplep-syres.2016.08.001. Epub 2016 Aug 4.; Steinhoff BJ, Hamer H, Trinka E, et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res. 2014 Jul;108(5):986-8. doi:10.1016/j.eplepsyres.2014.03.015. Epub 2014 Mar 27.; Steinhoff BJ, Bacher M, Bast T, et al. First clinical experiences with perampanel - the Kork experience in 74 patients. Epilepsia. 2014 Jan;55 Suppl 1:16-8. doi:10.1111/epi.12492.; Vlasov P, Karlov V, Zhidkova I, et al. Russian experience of using perampanel in daily clinical practice. Preliminary report. Journal of Epileptology. 2016;24 61-8.; Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012 May 15;78(20): 1548-54. doi:10.1212/WNL.0b013e3182563b19. Epub 2012 May 9.; Shah E, Reuber M, Goulding P, et al. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure. 2016 Jan;34:1-5. doi:10.1016/j.seizure.2015.10.017. Epub 2015 Nov 10.; Rohracher A, Zimmermann G, Villanueva V, et al. Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia. 2018 Sep;59(9):1727-39. doi:10.1111/epi.14520. Epub 2018 Jul 25.; Renroe B, Yang H, Williams B. Interim efficacy and safety analysis of adjunctive perampanel in the adolescent population from the extension phase of 3 double-blind, placebo-controlled phase 3 (core) studies in patients with refractory partial-onset seizures. 42nd Annual Meeting of the Child Neurology Society; 30 Oct-2 Nov 2013; Austin, TX, USA, 2013.; Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: An expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013 Jan;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x. Epub 2012 Sep 20.; Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behav Neurol. 2018 Nov 15;2018: 2064027. doi:10.1155/2018/2064027. eCollection 2018.; Meador KJ, Yang H, Pina-Garza JE, et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia. 2016 Feb;57(2):243-51. doi:10.1111/epi.13279. Epub 2016 Jan 1.; Jaramillo JA, Estevez Maria JC, Giron Ubeda JM, et al. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON). Epilepsy Behav. 2020 Jan;102:106655. doi:10.1016/j.yebeh.2019.106655. Epub 2019 Dec 6.; https://nnp.ima-press.net/nnp/article/view/1365